−0.080AUD
−15.29 MAUD
17.03 MAUD
220.16 M
About NOVA EYE MEDICAL LIMITED
Sector
Industry
CEO
Thomas Spurling
Website
Headquarters
Kent Town
Founded
1970
ISIN
AU0000094252
FIGI
BBG000BT1XB7
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EYE is 0.250 AUD — it has decreased by 5.66% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange NOVA EYE MEDICAL LIMITED stocks are traded under the ticker EYE.
NOVA EYE MEDICAL LIMITED is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
EYE stock is 6.00% volatile and has beta coefficient of −0.14. Check out the list of the most volatile stocks — is NOVA EYE MEDICAL LIMITED there?
One year price forecast for NOVA EYE MEDICAL LIMITED has a max estimate of 0.600 AUD and a min estimate of 0.600 AUD.
EYE earnings for the last quarter are −0.01 AUD per share, whereas the estimation was −0.01 AUD resulting in a −4.72% surprise. The estimated earnings for the next quarter are −0.01 AUD per share. See more details about NOVA EYE MEDICAL LIMITED earnings.
NOVA EYE MEDICAL LIMITED revenue for the last quarter amounts to 8.39 M AUD despite the estimated figure of 8.30 M AUD. In the next quarter revenue is expected to reach 10.14 M AUD.
Yes, you can track NOVA EYE MEDICAL LIMITED financials in yearly and quarterly reports right on TradingView.
EYE stock has fallen by 9.09% compared to the previous week, the month change is a 19.05% rise, over the last year NOVA EYE MEDICAL LIMITED has showed a 6.64% decrease.
EYE net income for the last quarter is −5.63 M AUD, while the quarter before that showed −8.69 M AUD of net income which accounts for 35.26% change. Track more NOVA EYE MEDICAL LIMITED financial stats to get the full picture.
Today NOVA EYE MEDICAL LIMITED has the market capitalization of 60.63 M, it has increased by 10.42% over the last week.
Like other stocks, EYE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVA EYE MEDICAL LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVA EYE MEDICAL LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVA EYE MEDICAL LIMITED stock shows the neutral signal. See more of NOVA EYE MEDICAL LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NOVA EYE MEDICAL LIMITED future price: according to them, EYE price has a max estimate of 0.60 AUD and a min estimate of 0.60 AUD. Read a more detailed NOVA EYE MEDICAL LIMITED forecast: see what analysts think of NOVA EYE MEDICAL LIMITED and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVA EYE MEDICAL LIMITED EBITDA is −7.63 M AUD, and current EBITDA margin is −56.11%. See more stats in NOVA EYE MEDICAL LIMITED financial statements.